Patents by Inventor Vincent R. Zurawski

Vincent R. Zurawski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conserved HBV and HCV sequences useful for gene silencing
    Patent number: 10982212
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 20, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING
    Publication number: 20190100757
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Application
    Filed: April 27, 2018
    Publication date: April 4, 2019
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • Conserved HBV and HCV sequences useful for gene silencing
    Patent number: 9982263
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: May 29, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING
    Publication number: 20160177310
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Application
    Filed: October 23, 2015
    Publication date: June 23, 2016
    Inventors: Catherine J. Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • Conserved HBV and HCV sequences useful for gene silencing
    Patent number: 9200281
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: December 1, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof
    Patent number: 9034303
    Abstract: 8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective MAO-AB inhibitory activities.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: May 19, 2015
    Inventors: Vincent R. Zurawski, Jr., David M. Stout, Theodore J. Nitz, Moussa B. H. Youdim, Orly Weinreb
  • Iron Chelators And Uses Thereof
    Publication number: 20150025085
    Abstract: 8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, 8(phosphoryloxy)methyl, and 8-carbamates derivatives thereof substituted at the 5-position are described as useful for iron chelation and neuroprotective therapies.
    Type: Application
    Filed: January 30, 2013
    Publication date: January 22, 2015
    Inventors: Vincent R. Zurawski, JR., Theodore J. Nitz
  • CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING
    Publication number: 20140273213
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Application
    Filed: October 1, 2013
    Publication date: September 18, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • NEUROPROTECTIVE AND NEURO-RESTORATIVE IRON CHELATORS AND MONOAMINE OXIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140186280
    Abstract: 8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective MAO-AB inhibitory activities.
    Type: Application
    Filed: March 4, 2014
    Publication date: July 3, 2014
    Inventors: Vincent R. ZURAWSKI, JR., David M. STOUT, Theodore J. NITZ, Moussa B.H. YOUDIM, Orly WEINREB
  • NEUROPROTECTIVE AND NEURO-RESTORATIVE IRON CHELATORS AND MONOAMINE OXIDASE INHIBITORS AND USES THEREOF
    Publication number: 20130330284
    Abstract: 8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective MAO-AB inhibitory activities.
    Type: Application
    Filed: August 12, 2011
    Publication date: December 12, 2013
    Applicant: VARINEL INC
    Inventors: Vincent R. Zurawski, David M. Stout, Theodore J. Nitz, Moussa B.H. Youdim, Orly Weinreb
  • Conserved HBV and HCV sequences useful for gene silencing
    Patent number: 8575327
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: November 5, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Catherine J. Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • Conserved HBV and HCV sequences useful for gene silencing
    Patent number: 8350021
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Grant
    Filed: June 10, 2004
    Date of Patent: January 8, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Catherine J. Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Jr., Liat Mintz
  • CONSERVED HBV AND HCV SEQUENCES USEFUL FOR GENE SILENCING
    Publication number: 20120035240
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Application
    Filed: December 12, 2005
    Publication date: February 9, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: CATHERINE J. PACHUK, CHANDRASEKHAR SATISHCHANDRAN, VINCENT R. ZURAWSKI, JR., LIAT MINTZ
  • Conserved Hbv and Hcv Sequences Useful for Gene Silencing
    Publication number: 20080070854
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Application
    Filed: June 10, 2004
    Publication date: March 20, 2008
    Applicant: Nucleonics, Inc.
    Inventors: Catherine J. Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski Jr., Liat Mintz
  • Hepatitis C virus vaccine
    Patent number: 6831169
    Abstract: Nucleic acid molecule that comprise an incomplete hepatitis C viral genome are provided. Pharmaceutical compositions that contain nucleic acid molecules comprising an incomplete hepatitis C viral genome including a nucleotide sequence encoding a complete hepatitis C core protein operably linked to regulatory elements functional in human cells are provided. Methods of immunizing individuals susceptible to or infected by hepatitis C virus comprising the step of administering such pharmaceutical compositions are provided.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: December 14, 2004
    Assignee: The General Hospital Corporation
    Inventors: Catherine J. Pachuk, Jack Wands, Takaji Wakita, Vincent R. Zurawski, Jr., Leslie R. Coney
  • Hepatitis C virus vaccine
    Publication number: 20020161218
    Abstract: Nucleic acid molecule that comprise an incomplete hepatitis C viral genome including specifically disclosed DNA sequences are disclosed. Pharmaceutical compositions that contain nucleic acid molecules comprising an incomplete hepatitis C viral genome including a nucleotide sequence encoding a complete hepatitis C core protein operably linked to regulatory elements functional in human cells are disclosed.
    Type: Application
    Filed: May 1, 2001
    Publication date: October 31, 2002
    Applicant: Apollon, Inc.
    Inventors: Catherine J. Pachuk, Jack Wands, Takaji Wakita, Vincent R. Zurawski, Leslie R. Coney
  • Hepatitis C virus vaccine
    Patent number: 6235888
    Abstract: Nucleic acid molecule that comprise an incomplete hepatitis C viral genome including specifically disclosed DNA sequences are disclosed. Pharmaceutical compositions that contain nucleic acid molecules comprising an incomplete hepatitis C viral genome including a nucleotide sequence encoding a complete hepatitis C core protein operably linked to regulatory elements functional in human cells are disclosed. Methods of immunizing individuals susceptible to or infected by hepatitis C virus comprising the step of administering such pharmaceutical compositions are disclosed.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: May 22, 2001
    Assignees: The General Hospital Corporation, Apollon, Inc.
    Inventors: Catherine J. Pachuk, Jack Wands, Takaji Wakita, Vincent R. Zurawski, Jr., Leslie R. Coney
  • Immunoassay utilizing monoclonal high affinity IgM antibodies
    Patent number: 5422239
    Abstract: Hybridomally produced monoclonal IgM antibodies having high affinity are useful for the immunoassay and purification of vital antigens.
    Type: Grant
    Filed: May 15, 1987
    Date of Patent: June 6, 1995
    Assignee: General Hospital Corporation
    Inventors: Jack R. Wands, Vincent R. Zurawski, Jr.
  • Method of isolating CA 125 antigen
    Patent number: 5059680
    Abstract: A preparation of an isolated immunoreactive CA 125 Antigen, and a method of isolating it is disclosed. CA 125 Antigen is a glycoprotein having a molecular weight of about 200kD, and a carbohydrate-content of about 24%. The CA 125 Antigen is isolated from a cell culture medium by acid precipitation, and is subsequently purified by size exclusion chromatography and immunoaffinity chromatography.
    Type: Grant
    Filed: November 24, 1986
    Date of Patent: October 22, 1991
    Assignee: Centocor, Inc.
    Inventors: Hugh M. Davis, Thomas L. Klug, Vincent R. Zurawski, Jr.
  • Monoclonal IgM antibody with specificity against hepatitis B surface antigen
    Patent number: 4973669
    Abstract: The monoclonal antibodies are specific for a determinant found on hepatitis B surface antigen, and show high affinity for this determinant. Hybridomally produced monoclonal IgM antibodies having high affinity are useful for the immunoassay and purification of viral antigens.
    Type: Grant
    Filed: June 3, 1988
    Date of Patent: November 27, 1990
    Assignee: Massachusetts General Hospital
    Inventors: Jack R. Wands, Vincent R. Zurawski, Jr., Hubert J. P. Schoemaker